FDA Panel Backs Eisai/MGI's Aquavan - With Proviso
This article was originally published in PharmAsia News
Executive Summary
FDA's Anesthetic and Life Support Drugs Advisory Committee voted 6-3 with one abstention May 7 to recommend approval of Eisai/MGI Pharma's Aquavan (fospropofol) for sedation in adult patients undergoing diagnostic or therapeutic procedures
You may also be interested in...
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors
U.S. FDA Rejects Eisai’s Aquavan Injection
Despite a recent advisory panel vote recommending clearance, albeit with strings attached, U.S. FDA has deemed Eisai's Aquavan, a mild-to-moderate sedative for colonoscopies and other procedures, "not approvable.